Remacemide-FPL-12924-生命科学试剂-MCE

Hotline:400-820-3792Inhibitors • ScreeningLibraries • Proteinswww.MedChemERemacemideCat.No.:HY-160604CASNo.:128298-28-2Synonyms:FPL12924;PR934-423;FPL13592分子式:C₁₇H₂₀N₂O分子量:268.35作用靶点:iGluR作用通路:MembraneTransporter/IonChannel;NeuronalSignaling储存方式:Powder-20°C3yearsInsolvent-80°C6months-20°C1month溶解性数据体外实验DMSO:87.5mg/mL(326.07mM;Needultrasonic)SolventMass1mg5mg10mgConcentration制备储备液1mM3.7265mL18.6324mL37.2648mL5mM0.7453mL3.7265mL7.4530mL10mM0.3726mL1.8632mL3.7265mL请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。储备液的保存方式和期限：-80°C,6months;-20°C,1month。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。BIOLOGICALACTIVITY生物活性Remacemide(FPL12924)是一种具有口服活性、非竞争性、低亲和力NMDA受体拮抗剂。Remacemide在缺氧和缺血性中风的动物模型中表现出神经保护活性。Remacemide也是一种抗惊厥试剂，可用于帕金森病和亨廷顿病的研究。IC50&TargetNMDAReceptor1/2 MasterofBioactiveMolecules—您身边的抑制剂大师www.MedChemEREFERENCESSchachterSC,etal.Remacemide:currentstatusandclinicalapplications.ExpertOpinInvestigDrugs.2000Apr;9(4):871-83.DykerAG,etal.Remacemidehydrochloride:adouble-blind,placebo-controlled,safetyandtolerabilitystudyinpatientswithacuteischemicstroke.Stroke.1999Sep;30(9):1796-801.GreenamyreJT,etal.Antiparkinsonianeffectsofremacemidehydrochloride,aglutamateantagonist,inrodentandprimatemodelsofParkinson'sdisease.AnnNeurol.1994Jun;35(6):655-61.KieburtzK,etal.AcontrolledtrialofremacemidehydrochlorideinHuntington'sdisease.MovDisord.1996May;11(3):273-7.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.Tel:400-820-3792/p>